Modus Therapeutics Holding AB

MODTX · Nasdaq Stockholm · Healthcare

0.39SEK 0.0%last day

Price as of 2 October 2026

The price over the past year, with dividends: −21.2%

Performance

1 month

−11.7%

1 year

−21.2%

3 years, per year

−41.1%

5 years, per year

−37.5%

Largest fall, 3 years

−94.3%

Below the peak now

−94.2%

Volatility, 1 year

73.2%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

5.1

Dividend yield

0.0%

Return on equity

−171.8%

Net margin

–

Market value

5 m USD

Quality, value and trend

Where Modus Therapeutics Holding stands against every Nordic stock today. 100 is best.

Quality93

Profitability and a sound balance sheet over time. Better than 93% of Nordic stocks.

Value2

The price measured against earnings, assets and cash flow. Better than 2% of Nordic stocks.

Trend70

The price development over the past year. Better than 70% of Nordic stocks.

Combined56

Quality, value and trend together. Better than 56% of Nordic stocks.

About Modus Therapeutics Holding

Modus Therapeutics Holding AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 2 employees.

Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. It develops Sevuparin, a lipopolysaccharide in Phase IIa trial to treat patients with sepsis, septic shock, anemia associated with chronic kidney disease, endotoxemia, severe malaria, and other diseases involving severe systemic inflammation. Modus Therapeutics Holding AB (publ) was founded in 2011 and is headquartered in Stockholm, Sweden.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis